

BIOMARIN PHARMACEUTICAL INC

Form 4

June 03, 2008

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB  
Number: 3235-0287Expires: January 31,  
2005Estimated average  
burden hours per  
response... 0.5Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BAFFI ROBERT**

(Last) (First) (Middle)

**C/O BIOMARIN  
PHARMACEUTICAL INC., 105  
DIGITAL DRIVE**

(Street)

**NOVATO, CA 94949**

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading  
Symbol**BIOMARIN PHARMACEUTICAL  
INC [BMRN]**3. Date of Earliest Transaction  
(Month/Day/Year)  
**05/30/2008**4. If Amendment, Date Original  
Filed(Month/Day/Year)5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☐ Director ☐ 10% Owner  
☒ Officer (give title below) ☐ Other (specify  
below) **SVP, Technical Operations**6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |        |            |          | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|----------------------------------------------------|--------------------------------|-------------------------------------------------------------------|--------|------------|----------|-----------------------------------------------------------------------------------------------|----------------------------------------------------------|-----------------------------------|
|                                 |                                      |                                                    | Code                           | V                                                                 | Amount | (A) or (D) | Price    |                                                                                               |                                                          |                                   |
| Common Stock                    | 05/30/2008 <sup>(1)</sup>            | 05/30/2008                                         | S                              |                                                                   | 100    | D          | \$ 38.62 | 37,434                                                                                        | D                                                        |                                   |
| Common Stock                    | 05/30/2008 <sup>(1)</sup>            | 05/30/2008                                         | S                              |                                                                   | 100    | D          | \$ 38.64 | 37,334                                                                                        | D                                                        |                                   |
| Common Stock                    | 05/30/2008 <sup>(1)</sup>            | 05/30/2008                                         | S                              |                                                                   | 200    | D          | \$ 38.68 | 37,134                                                                                        | D                                                        |                                   |
| Common Stock                    | 05/30/2008 <sup>(1)</sup>            | 05/30/2008                                         | S                              |                                                                   | 200    | D          | \$ 38.7  | 36,934                                                                                        | D                                                        |                                   |
|                                 | 05/30/2008 <sup>(1)</sup>            | 05/30/2008                                         | S                              |                                                                   | 100    | D          |          | 36,834                                                                                        | D                                                        |                                   |

# Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

|        |                           |            |   |     |   |       |        |   |
|--------|---------------------------|------------|---|-----|---|-------|--------|---|
| Common |                           |            |   |     |   | \$    |        |   |
| Stock  |                           |            |   |     |   | 38.76 |        |   |
| Common | 05/30/2008 <sup>(1)</sup> | 05/30/2008 | S | 400 | D | \$    | 36,434 | D |
| Stock  |                           |            |   |     |   | 38.77 |        |   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2. Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. Transaction<br>Code<br>(Instr. 8) | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3,<br>4, and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and<br>Amount of<br>Underlying<br>Securities<br>(Instr. 3 and 4) | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number<br>of<br>Derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction<br>(Instr. 6) |
|-----------------------------------------------------|--------------------------------------------------------------------|-----------------------------------------|-------------------------------------------------------------|--------------------------------------|--------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
|                                                     |                                                                    |                                         |                                                             | Code                                 | V (A) (D)                                                                                                          | Date<br>Exercisable                                            | Expiration<br>Date                                                        | Title                                               | Amount<br>or<br>Number<br>of<br>Shares                                                                                     |

## Reporting Owners

### Reporting Owner Name / Address

### Relationships

Director 10% Owner Officer Other

BAFFI ROBERT  
C/O BIOMARIN PHARMACEUTICAL INC.  
105 DIGITAL DRIVE  
NOVATO, CA 94949

SVP, Technical Operations

## Signatures

G. Eric Davis,  
Attorney-in-Fact 06/03/2008

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to a Rule 10b5-1 Trading Plan executed February 29, 2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

## Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.